miRecule is a pre-clinical biotechnology company focused on the development of RNA therapeutics to treat a variety of diseases. miRecule has developed the DREAmiR genomics-based discovery platform to identify critical RNA targets for drug development in specific subsets of patients that would benefit from treatment. The company then creates proprietary chemically-modified RNA therapeutics with improved pharmacology, while utilizing antibodies for targeted delivery to the diseased tissue. miRecule's lead candidate, MC-30 for Head & Neck cancer, replaces the potent tumor suppressor activity of microRNA-30 which is lost in half of Head & Neck cancer patients. miRecule's second program, MC-DX4 for the treatment of Facioscapulohumeral muscular dystrophy (FSHD). MC-DX4 eliminates expression of the DUX4 gene, which causes the disease in 95% of patients.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 05/27/21 | $5,700,000 | Seed |
Alexandria Venture Investments Alumni Ventures Group Boutique Venture Partners FSHD Society Maryland Momentum Fund Pathway Bioventures | undisclosed |
